Other examples include use of blood concentrations of prostate specific antigen (PSA) in prostate cancer, carcinoembryonic antigen (CEA) in colorectal and lung cancers and cancer antigen 125 (CA-125) in ovary cancer. This evidence concerns the gene KLK3 and prostate cancer.